Posaconazole for COVID-19: real-time analysis

Download Image

Post

c19early.org

Posaconazole for COVID-19

1 study with 249 patients

Serious outcome risk

Posaconazole

Control

COVID-19 Posaconazole studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−131%

Mortality (1)−131%

Prophylaxis (1)−131%

00.511.5+

← Posaconazole
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Jan 12 2025	Prattes et al., Mycoses, doi:10.1111/myc.70023	Posaconazole for Prevention of COVID‐19‐Associated Pulmonary Aspergillosis in Mechanically Ventilated Patients: A European Multicentre Case–Control Study (POSACOVID)
Jan 12 2025	131% higher mortality (p<0.0001) and 54% improvement (p=0.41). Prospective matched case-control study of 249 mechanically ventilated COVID-19 patients in Europe, showing variable impact of posaconazole prophylaxis on COVID-19-associated pulmonary aspergillosis (CAPA) incidence depending on baseline C..